AIFA simplifies pricing and reimbursement procedure for biosimilars
The Italian Medicines Agency’s (AIFA) CTS and CPR Advisory Commissions have released a new simplified pricing and reimbursement procedure for … read more »
Testing requirements are likely slowing biosimilar entries in the US
New analysis suggests a high testing bar for biosimilars to gain regulatory approval is another contributing factor for slowing biosimilar … read more »
MHRA drafts guidance on licensing of biosimilar products
The Medicines and Healthcare products Regulatory Agency (MHRA) has released draft guidance for biosimilar products in the UK. This … read more »
AIFA Biosimilars monitoring reports
AIFA – Agenzia Italiana del Farmaco (Italian Medicines Agency) has published an in-depth analysis on consumption trends for biosimilars for … read more »
Biosimilar uptake in the US lags behind the EU
A new report suggests relatively low uptake of biosimilars in the US could be costing healthcare providers billions in lost … read more »
Irish hospitals may be offered incentives to switch to biosimilars
It has been reported that the Irish HSE is to incentivise hospitals to promote the use of biosimilars in place … read more »
Canadian provinces increase use of biosimilar drugs
National and provincial Canadian governments are increasingly employing strategies to drive use of biosimilars ahead of originator products to achieve … read more »
Generics and biosimilars to benefit from SPC manufacturing waiver
A new SPC exemption will level the playing field between EU and non-EU generic and biosimilar manufacturers, and will prevent … read more »
2019 Biosimilars Commercialisation Summit in Amsterdam
MAP BioPharma are a media partner of the Biosimilars Commercialisation Summit.The conference will cover every aspect of getting your biosimilars … read more »
Improvement of GSAV Regulations – A BPI Response
The Bundestag Health Committee is seeking to clarify the Gesetz für mehr Sicherheit in der Arzneimittelversorgung (GSAV), (Greater Security in … read more »
